文献速递胸部肿瘤

纳武利尤单抗联合伊匹木单抗对比化疗一线治疗高肿瘤突变负荷晚期非小细胞肺癌:随机开放标签III期CheckMate 227试验的患者报告结局

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
PubMed 文献 · Eur J Cancer · 2019-06-11

在III期CheckMate 227研究中,一线纳武利尤单抗联合伊匹木单抗对比化疗显著延长高肿瘤突变负荷(≥10个突变/兆碱基)晚期非小细胞肺癌患者的无进展生存期。本文评估该人群的患者报告结局,显示联合治疗组在肺癌症状量表平均症状负担指数、三项全局指数及EQ-5D视觉模拟评分和效用指数上较基线早期出现有临床意义的改善;第12周症状恶化率联合组为22.3%,化疗组为35.0%,绝对风险降低12.7%(95%CI 2.4-22.5)。

要点

  • 高TMB晚期NSCLC患者中,纳武利尤单抗联合伊匹木单抗较化疗早期且持续改善患者报告结局。
  • 第12周症状恶化率联合组22.3% vs 化疗组35.0%,绝对风险降低12.7%(95%CI 2.4-22.5)。
  • 联合组LCSS ASBI/3-IGI和EQ-5D VAS/UI较基线早期出现有临床意义的改善,化疗组症状和健康相关生活质量保持稳定或诱导后改善。

核心结论

  • 一线纳武利尤单抗联合伊匹木单抗在高TMB晚期NSCLC患者中较化疗显示出早期、持续的患者报告结局改善。

研究设计与样本

  • III期CheckMate 227研究(NCT02477826)的患者报告结局分析,随机、开放标签。
  • 评估人群为高肿瘤突变负荷(≥10个突变/兆碱基)的晚期非小细胞肺癌患者。
  • 使用经验证的肺癌症状量表(LCSS)和EQ-5D问卷评估疾病相关症状和总体健康状况。

主要发现

  • 高TMB人群中,基线时PRO问卷完成率约90%,大多数治疗期间评估完成率>80%。
  • 治疗期间,纳武利尤单抗联合伊匹木单抗组LCSS ASBI/3-IGI和EQ-5D VAS/UI较基线显示早期、有临床意义的改善;化疗组症状和健康相关生活质量保持稳定(LCSS ASBI/3-IGI、EQ-5D UI)或诱导后改善(EQ-5D VAS)。
  • 混合效应模型重复测量(MMRM)评估显示,纳武利尤单抗联合伊匹木单抗组症状负担改善优于化疗组。
  • 第12周症状恶化率联合组为22.3%,化疗组为35.0%,绝对风险降低12.7%(95%CI 2.4-22.5),与是否停药无关。
  • LCSS和EQ-5D汇总指标中,联合组至首次恶化时间较化疗组延迟。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the phase III CheckMate 227 study, first-line nivolumab + ipilimumab significantly prolonged progression-free survival (co-primary end-point) versus chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) and high tumour mutational burden (TMB; ≥10 mutations/megabase). AIM: To evaluate patient-reported outcomes (PROs) in this population. METHODS: Disease-related symptoms and general health status were assessed using the validated PRO questionnaires Lung Cancer Symptom Scale (LCSS) and EQ-5D, respectively. LCSS average symptom burden index (ASBI) and three-item global index (3-IGI) and EQ-5D visual analogue scale (VAS) and utility index (UI) scores and changes from baseline were analysed descriptively. Longitudinal changes were assessed by mixed-effect model repeated measures (MMRMs) and time to first deterioration/improvement analyses. RESULTS: In the high TMB population, PRO questionnaire completion rates were ∼90% at baseline and >80% for most on-treatment assessments. During treatment, mean changes from baseline with nivolumab + ipilimumab showed early, clinically meaningful improvements in LCSS ASBI/3-IGI and EQ-5D VAS/UI; with chemotherapy, symptoms and health-related quality of life remained stable (LCSS ASBI/3-IGI, EQ-5D UI) or improved following induction (EQ-5D VAS). MMRM-assessed changes in symptom burden were improved with nivolumab + ipilimumab versus chemotherapy. Symptom deterioration by week 12 was lower with nivolumab + ipilimumab versus chemotherapy (22.3% versus 35.0%; absolute risk reduction: 12.7% [95% confidence interval 2.4-22.5]), irrespective of discontinuation. Time to first deterioration was delayed with nivolumab + ipilimumab versus chemotherapy across LCSS and EQ-5D summary measures. CONCLUSION: First-line nivolumab + ipilimumab demonstrated early, sustained improvements in PROs versus chemotherapy in patients with advanced NSCLC and high TMB. CLINICAL TRIAL REGISTRATION: NCT02477826.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Reck M, Schenker M, Lee KH, et al. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. Eur J Cancer. 2019. PMID: 31195357. doi:10.1016/j.ejca.2019.05.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。